HomePeptide dosagesLivagen
Livagen dosage: chart, reported range and vial math
No published study has given Livagen to people, so there is no human dose. The 2 to 5 mg a day for 10 to 20 days that people report comes from sellers and users. The research is in cultured cells and rats. It is not approved in the US or Canada.
Livagen dosage chart
Reported range, not a label dosePick your vial size. Each row shows the dose in milligrams or micrograms, the volume to draw and the mark on a U-100 syringe.
| Dose | Volume | Syringe units |
|---|---|---|
| 2 mg | 0.20 mL | 20 units |
| 5 mg | 0.50 mL | 50 units |
Source Reported range, not a label dose. Reports describe 2 to 5 mg a day for 10 to 20 days. No study has given Livagen to people; the published work is in cultured cells and rats. Vial math is arithmetic.
Which syringe fits each dose
For the 20 mg vial at 10 mg/mL.
| Dose | Volume | Units | 0.3 mL syringe | 0.5 mL syringe | 1 mL syringe |
|---|---|---|---|---|---|
| 2 mg | 0.20 mL | 20 units | Yes | Yes | Yes |
| 5 mg | 0.50 mL | 50 units | No | Yes | Yes |
How long a vial lasts
Whole doses in one vial. The row for the size picked above is marked.
| Vial | 2 mg | 5 mg |
|---|---|---|
| 20 mg vial | 10 doses | 4 doses |
How to mix a Livagen vial
These steps are for the 20 mg vial picked in the chart. Change the size there and the amounts here change with it.
- Wash your hands. Wipe the stopper of the peptide vial and the water vial with an alcohol swab.
- Draw 2 mL of bacteriostatic water into a syringe.
- Push the needle through the stopper of the peptide vial and let the water run slowly down the glass, not straight onto the powder.
- Swirl the vial gently until the powder is gone. Do not shake it.
- Write the date and 10 mg/mL on the vial, then put it in the fridge.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 20 mg vial | 2 mL | 10 mg/mL |
What Livagen is
Livagen is a synthetic tetrapeptide, Lys-Glu-Asp-Ala (KEDA), designed from the amino acid analysis of polypeptide preparations made from liver. [1]
Other names: Lyvagen, KEDA, Lys-Glu-Asp-Ala.
How it has been given to people: no human use on record; one rat study gave it by mouth.
What to know before reading a dose
- There is no human dose on record and no study in which people were given Livagen. The published work is in cultured cells, rat tissue and rats.
- The chromatin findings that Livagen is known for were made on blood cells from elderly donors treated in culture [2], [6]. They do not show what happens in a person given the peptide.
- Nearly all of the work comes from the St. Petersburg Institute of Bioregulation and Gerontology and a partner laboratory in Tbilisi that shares authors with it. No fully independent group has repeated it.
- Not an approved medicine in the US or Canada as of the check date. Health Canada warns against all unauthorized injectable peptide drugs [11].
What the evidence shows
Each finding is tagged by the kind of study it comes from. Human trials are listed first.
Animal study
Given by mouth to rats for two weeks, Livagen lowered digestive enzyme activity in young animals and raised it in old ones. The abstract gives no dose. [4]
Animal study
A 2020 review by the group that made the peptide says a calf liver extract and the KEDA peptide worked well in animal and cell models of hepatitis and liver scarring. The abstract describes no human study. The quote is as printed, including the misspelling. [5]
Lab study
In blood lymphocytes taken from old people and treated in culture, Livagen switched ribosomal genes back on and loosened tightly packed chromatin. The cells were treated, not the people. [2]
Lab study
In cultured lymphocytes from donors aged 80 to 91, a separate Georgian laboratory reported the same loosening of packed chromatin with Livagen. [6]
Lab study
In cultured liver cells from rats aged 1 to 24 months, Livagen raised protein synthesis, most of all in cells from old animals. [1]
Lab study
In a test tube, Livagen blocked enzymes in human blood serum that break down enkephalins. It did not bind opioid receptors from rat brain. Serum was tested, not people. [3]
Lab study
In cultured lymphocytes from patients with ductal breast cancer, Livagen with cobalt ions was reported to reduce DNA breaks and chromosome abnormalities. This was done on cells in culture. [8]
Side effects and warnings
Reported in human studies or on a label:
- No human side-effect report for Livagen was found. Health Canada lists these risks for unauthorized injectable peptide drugs in general: hormonal imbalance, mood swings, blood sugar imbalance, liver or kidney damage, blood clots and growth of cancerous tumours. [11]
Livagen has no approved label in the US or Canada for this use, so there is no official list of who should not use it, no interaction list and no missed-dose rule.
Storage
Keep an unmixed vial the way its label says. Once it is mixed, keep it in the fridge, do not freeze it, and write the mixing date on the vial.
Livagen dosage questions
How many units is 5 mg of Livagen from a 20 mg vial?
Mixed with 2 mL of bacteriostatic water, a 20 mg vial is 10 mg/mL. 5 mg is 0.50 mL, which is 50 units on a U-100 syringe.
How much water goes in a 20 mg Livagen vial?
2 mL gives 10 mg/mL. At that strength the doses in the chart sit at 20, 50 units on a U-100 syringe.
How many doses are in a 20 mg vial?
Whole doses in one vial: 10 at 2 mg, 4 at 5 mg.
Is Livagen approved in the US?
Not FDA approved. No Livagen product is in Drugs@FDA, and it is not on the FDA page of bulk substances reviewed for compounding.
Is Livagen authorized in Canada?
No Livagen product is in the Health Canada Drug Product Database. Health Canada warns against all unauthorized injectable peptide drugs.
What human dosing data is there for Livagen?
There is no human dose on record and no study in which people were given Livagen. The published work is in cultured cells, rat tissue and rats.
Sources
Each one was opened on 10 Oct 2026 and matched to the line it supports.
- Brodskii VIa et al. [Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen]. Izv Akad Nauk Ser Biol 2001. PubMed 15926314.
- Khavinson VKh et al. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bull Exp Biol Med 2002. PubMed 12533768.
- Kost NV et al. [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. Izv Akad Nauk Ser Biol 2003. PubMed 12942748.
- Timofeeva NM et al. [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]. Adv Gerontol 2005. PubMed 16075683.
- Kuznik BI et al. [The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]. Adv Gerontol 2020. PubMed 32362099.
- Lezhava T et al. Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Ann N Y Acad Sci 2007. PubMed 17460203.
- Riadnova IIu et al. [Functional morphology of an organotypic liver culture exposed to the peptide livagen]. Adv Gerontol 2002. PubMed 12577697.
- Jokhadze T et al. [EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION]. Georgian Med News 2017. PubMed 28574395.
- US Food and Drug Administration openFDA search of Drugs@FDA: livagen 2026. api.fda.gov.
- US Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026. fda.gov.
- Health Canada Think twice before injecting peptides bought online: unauthorized products can seriously harm you 2026. recalls-rappels.canada.ca.
- Health Canada Health Canada Drug Product Database, active ingredient search: livagen 2026. health-products.canada.ca.
- US National Library of Medicine ClinicalTrials.gov search, intervention: livagen 2026. clinicaltrials.gov.
Looked for and not found
- No published study in which Livagen was given to people. The human material in the literature is blood cells or serum taken from donors and treated in the laboratory.
- No injected dose in any abstract read, human or animal. The one live-animal study found gave it by mouth to rats and its abstract states no dose [4].
- No study in people showing a liver benefit. The liver findings are from cultured rat liver cells and from animal models described in a review.
- No human half-life or other pharmacokinetic figure. One abstract says gut enzymes barely break the peptide down, which was measured in rat intestine [4].
- No trial registered on ClinicalTrials.gov: searches for livagen returned no studies [13].
- No approved label in the US or Canadian sources searched, so no official dose, contraindications, interaction list or storage instructions.
- No human side-effect or safety data.
Change log
10 Oct 2026Page published. 13 sources checked. Vial math added for the 20 mg vial.
Related
MOTS-c dosageEpitalon dosageNAD+ dosageSS-31 (elamipretide) dosageCardiogen dosage20 mg vialWhat Livagen isLongevityPeptide dosage chartDosage calculator
DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.